Speech: A Translational Approach to Evaluate T Cell Engagers & Bispecific Antibodies in Humanized Animal Models

• Development of Co-inoculated tumor/PBMC animal models to assess the efficacy and immune-mediated mechanisms of T cell engagers and bispecific antibodies
• Application of IO-FIVE, a humanized MiniPDX platform to evaluate T cell engagers in fresh patient-derived samples
• Establishment of clinically relevant animal models to support candidate selection and optimization

Speakers:

Bin Xie

Vice President, Research & Executive Director, Immuno-Oncology

Shanghai Lide Biotech Co. Ltd.